Ranbaxy Laboratories Ltd, the country's top drugmaker by sales, reported a quarterly loss of Rs 2,983 crore, mainly due to a provision related to a probe by the US Justice Department.
The company said it set aside Rs 2,648 crore as a provision towards settlement of the probe related to compliance issues at the drugmaker's manufacturing facilities in the United States and India.
Ranbaxy, majority owned by Japan's Daiichi Sankyo Co, said consolidated net sales soared 79.2% in the December quarter at Rs 3,738 crore.
Valued at $3.85 billion, shares in Ranbaxy fell 21.2% in October-December when the benchmark healthcare index was little changed.
